Amplify Weight Loss Drug & Treatment ETF (THNR): ETF
ETF traded on ARCX under symbol THNR. Quoted in usd.
Amplify Weight Loss Drug & Treatment ETF
+0.67%$25.91
ARCX:THNREquity
AUM $5.15M·YTD --·Yield --
ARCX:THNR$25.91+0.67%AUM $5.15MAbout THNR
The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Largest holdings
- LLY Eli Lilly & Co11.49%
- NVO Novo Nordisk A/S8.72%
- AMGN Amgen Inc6.12%
- AZN AstraZeneca PLC5.93%
- REGN Regeneron Pharmaceuticals Inc5.79%
- GILD Gilead Sciences Inc5.69%
- ROP.SW Roche Holding AG5.66%
- ABBV AbbVie Inc5.65%
- PFE Pfizer Inc5.40%
- 4519.T Chugai Pharmaceutical Co Ltd5.01%
Dividend History
Benchmark Comparison
Compared against
Performance Returns
Drawdown Chart
Analyst Coverage
Savings Plan Calculator
Total Invested
$70,000
Final Portfolio
$109,455
Total Return
+$39,455
(+56.4%)
Dividends Reinvested
$0
compounded into portfolio
Defaults are seeded from historical performance and trailing twelve-month yield. Past performance is not a forecast. Feel free to adjust any input to model your own assumptions.
ETF Key Metrics
AUM$5.15M
NAV$25.75
Premium/Discount+0.64%
Expense Ratio0.59%
Market Cap$5.29M
Shares Outstanding200.00K
Inception DateMay 21, 2024
Fund Details
52-Week Range
$23.40$27.94
Current: $25.91
Volume
Volume1.52K
Avg Volume1.38K
Vol/Avg1.10x
30d
812
60d
792
90d
1.26K
Comparable ETFs